Fate Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the fiscal quarter ended June 30, 2026, disclosing financial condition, operational risks, and share count data as of August 6, 2026.

Key Highlights

  • Shares outstanding: As of August 6, 2026, 119,820,514 shares of common stock, par value $0.001 per share, were issued and outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • iPSC platform: The company disclosed it has multiple iPSC-derived cell product candidates currently undergoing clinical and preclinical development.
  • Funding risk: The filing states that development of product candidates "will require substantial additional funding," which if available "may cause dilution to our stockholders."
  • Regulatory uncertainty: The company noted that the regulatory approval process for its novel product candidates is "particularly uncertain" and candidates could fail to receive FDA or comparable foreign regulatory authority approval for multiple stated reasons.

Fate Therapeutics Quarterly Disclosure: iPSC Pipeline, Funding, and Regulatory Risks

Fate Therapeutics, Inc. (NASDAQ:FATE), headquartered at 12278 Scripps Summit Drive, San Diego, CA 92131, filed its Form 10-Q for the quarterly period ended June 30, 2026 on August 13, 2026. The filing covers condensed consolidated financial statements, management discussion, and an extensive set of risk factors related to the company's clinical-stage cell therapy programs built on its proprietary induced pluripotent stem cell (iPSC) platform.

According to the filing, the company's product candidates and programs "represent novel therapeutic approaches" and may fail to demonstrate the "safety, potency, durability, and efficacy necessary to support further development or commercialization." The registrant disclosed that it may deprioritize or discontinue clinical development of one or more product candidates based on data from ongoing trials, prioritization decisions, or the competitive environment for the relevant disease areas. The filing also noted that one or more candidates undergoing clinical development may have therapeutic potential in more than one disease area, and the company may elect to prioritize one disease area over another.

Among the operational risks described, the filing cited dependence on third-party suppliers including sole source suppliers, limited experience manufacturing product candidates on a clinical scale, and no experience manufacturing on a commercial scale. The company also flagged potential disruptions from "inadequate funding for the FDA, SEC, the National Institutes of Health and other government agencies, as well as changes in personnel and policy priorities at these agencies" as factors that could hinder its ability to develop or commercialize new products. Federal legislative and regulatory efforts, including reference pricing, most-favored-nation pricing models, and potential tariffs on pharmaceutical products, were also identified as areas of concern in the risk summary.

What Was Disclosed

Fate Therapeutics filed a quarterly Form 10-Q covering the period ended June 30, 2026, reporting 119,820,514 shares outstanding as of August 6, 2026, and disclosing operational, funding, manufacturing, and regulatory risks tied to its iPSC-based cell therapy pipeline.